Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Akero Therapeutics Inc
AKROCurrent price
21.87 USD
-0.94 USD (-4.12%)
Last closed
22.63 USD
Company
www.akerotx.com
ISIN
US00973Y1082
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
2 040 230 528 USD
Yield for 12 month
-0.73 %
1Y
3Y
5Y
10Y
15Y
AKRO
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. Address: 601 Gateway Boulevard, South San Francisco, CA, United States, 94080
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
48.27 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
-29 000 USD
Last Year
-260 000 USD
Current Quarter
–
Last Quarter
-1 000 USD
Key Figures AKRO
1 year
3 years
5 years
10 years
EBITDA
-269 265 984 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-23.17 %
PEG Ratio
–
Return On Equity TTM
-35.90 %
Wall Street Target Price
48.27 USD
Revenue TTM
–
Book Value
10.61 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-3.78 USD
Diluted Eps TTM
-3.78 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics AKRO
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History AKRO
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation AKRO
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
-6.77
Price Book MRQ
2.76
Financials AKRO
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators AKRO
For 52 weeks
15.32 USD
37.00 USD
50 Day MA
30.73 USD
Shares Short Prior Month
3 624 838
200 Day MA
25.94 USD
Short Ratio
4.86
Shares Short
3 287 084
Short Percent
4.85 %
BeatStart